Literature DB >> 11063818

Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement.

K B Abdul-Majid1, J Jirholt, C Stadelmann, A Stefferl, P Kjellén, E Wallström, R Holmdahl, H Lassmann, T Olsson, R A Harris.   

Abstract

We identified H-2(q) as a susceptible genotype for MOG-induced EAE by systematic screening of a series of H-2 congenic B10 mouse strains. A series of H-2(q)-bearing strains with divergent gene backgrounds were subsequently investigated. DBA/1 mice were highly susceptible to MOG(1-125)- and MOG(79-96)-induced EAE in the absence of pertussis toxin. Immunisation with MOG(1-125) and MOG(79-96) induced an autoreactive T-cell response in DBA/1 mice. Brain histopathology revealed T-cell and macrophage-infiltrated lesions with associated demyelination. The important features which make this an appropriate model of human disease are high sensitivity to MOG and dependence of an immunodominant peptide region homologous to that implicated in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063818     DOI: 10.1016/s0165-5728(00)00360-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

1.  GM-CSF is not essential for experimental autoimmune encephalomyelitis but promotes brain-targeted disease.

Authors:  Emily R Pierson; Joan M Goverman
Journal:  JCI Insight       Date:  2017-04-06

2.  Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.

Authors:  Ingunn M Stromnes; Lauren M Cerretti; Denny Liggitt; Robert A Harris; Joan M Goverman
Journal:  Nat Med       Date:  2008-02-17       Impact factor: 53.440

3.  HMGB1, a novel biomarker of inflammatory demyelinating disease: an interview with Dr. Robert A. Harris.

Authors:  Helene F Rosenberg
Journal:  J Leukoc Biol       Date:  2008-09-09       Impact factor: 4.962

4.  A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Ivana Nikić; Doron Merkler; Catherine Sorbara; Mary Brinkoetter; Mario Kreutzfeldt; Florence M Bareyre; Wolfgang Brück; Derron Bishop; Thomas Misgeld; Martin Kerschensteiner
Journal:  Nat Med       Date:  2011-03-27       Impact factor: 53.440

Review 5.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

6.  Myelin-specific CD8+ T cells exacerbate brain inflammation in CNS autoimmunity.

Authors:  Catriona A Wagner; Pamela J Roqué; Trevor R Mileur; Denny Liggitt; Joan M Goverman
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

7.  Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders.

Authors:  Thomas Stahnke; Christine Stadelmann; Anne Netzler; Wolfgang Brück; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

8.  Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene.

Authors:  Malin Hultqvist; Peter Olofsson; Jens Holmberg; B Thomas Bäckström; Jesper Tordsson; Rikard Holmdahl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

9.  A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis.

Authors:  Karen M Spach; Rajkumar Noubade; Ben McElvany; William F Hickey; Elizabeth P Blankenhorn; Cory Teuscher
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

10.  B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system.

Authors:  Emily R Pierson; Ingunn M Stromnes; Joan M Goverman
Journal:  J Immunol       Date:  2013-12-23       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.